IDF presentations highlight insulin sensitisers in type 2 diabetes: the new GMS contract emphasises effective management of type 2 diabetes. New ways of working with insulin sensitisers (glitazones) to specifically target insulin resistance and improve patient care were presented at the International Diabetes Federation Congress. Gwen Hall reports on these treatment innovations

The number of people suffering from diabetes--in particular type 2 diabetes--is escalating rapidly and is set to double in the next ten years. Why? An inactive lifestyle, coupled with poor [...]